Over the last decades, monoclonal antibodies have substantially improved the treatment of
several conditions. The continuous search for novel therapeutic targets and improvements in …

Previous studies have demonstrated the efficacy and feasibility of an anti-viral vaccine
strategy that takes advantage of pre-existing CD4+ helper T (Th) cells induced by …

Triple‐negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer that
remains an unmet medical need. Because TNBC cells do not express the most common …

Human natural history and vaccine studies support a protective role of antibody dependent
cellular cytotoxicity (ADCC) activity against many infectious diseases. One setting where this …

Some HIV-infected people develop broadly neutralizing antibodies (bNAbs) that block many
diverse, unrelated strains of HIV from infecting target cells and, through passive …

Despite significant advances in scientific research and the advent of treatment and
prevention strategies over the past several decades, the HIV/AIDS pandemic continues to …

As of the year 2023, there has yet to be developed an effective prophylactic vaccine against
HIV-1 infection. One likely reason for prior failures in vaccine trials is that vaccines have …

The disease active tuberculosis (TB) annually claims 1.5 million lives worldwide and was the
deadliest infectious disease caused by a single pathogen prior to COVID-19. Moreover, 2 …

Shalina has a Bachelor of Science degree in Biology from the University of Washington and
has been at FCSL for two years. Shalina is currently part of the Development Team as a …

It has now been nearly 40 years since the human immunodeficiency virus (HIV) was
discovered. Based on the CDC, an estimated 1.2 million individuals were infected with HIV …